ABSI Stock Overview
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Absci Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.71 |
| 52 Week High | US$6.72 |
| 52 Week Low | US$1.11 |
| Beta | 2.37 |
| 1 Month Change | -6.92% |
| 3 Month Change | 29.04% |
| 1 Year Change | 224.83% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.18% |
Recent News & Updates
Recent updates
Absci: Differentiated Antibody Discovery Play
Feb 27Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M
Aug 11Absci teams up to help develop antibody drugs for cancer
Jul 07Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out
Jan 10IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)
Jul 22Shareholder Returns
| ABSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.0% | 1.5% | 1.2% |
| 1Y | 224.8% | 1.1% | 24.7% |
Return vs Industry: ABSI exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: ABSI exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| ABSI volatility | |
|---|---|
| ABSI Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABSI's share price has been volatile over the past 3 months.
Volatility Over Time: ABSI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 155 | Sean McClain | www.absci.com |
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Absci Corporation Fundamentals Summary
| ABSI fundamental statistics | |
|---|---|
| Market cap | US$531.22m |
| Earnings (TTM) | -US$110.57m |
| Revenue (TTM) | US$5.72m |
92.9x
P/S Ratio-4.8x
P/E RatioIs ABSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABSI income statement (TTM) | |
|---|---|
| Revenue | US$5.72m |
| Cost of Revenue | US$47.57m |
| Gross Profit | -US$41.85m |
| Other Expenses | US$68.72m |
| Earnings | -US$110.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.98 |
| Gross Margin | -731.88% |
| Net Profit Margin | -1,933.65% |
| Debt/Equity Ratio | 4.5% |
How did ABSI perform over the long term?
See historical performance and comparison